Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773915 | 0.87 | NR4A2 (0.58) | NR4A2CYP2C9NPC1RAB9AGRM5 | |
| SCHEMBL1734081 | 0.86 | NR4A2 (0.57) | NR4A2CYP2C9NPC1RAB9AGRM5 | |
| SCHEMBL3779449 | 0.86 | NR4A2 (0.57) | NR4A2CYP2C9NPC1RAB9AGRM5 | |
| SCHEMBL1732978 | 0.84 | NR4A2 (0.80) | NR4A2CYP2C9GRM5 | |
| SCHEMBL3777392 | 0.84 | NR4A2 (0.55) | NR4A2CYP2C9NPC1RAB9AGRM5 | |
| SCHEMBL3773362 | 0.84 | KMT2A (0.59) | NR4A2CYP2C9RAB9AKMT2AMEN1 | |
| SCHEMBL1733042 | 0.83 | NR4A2 (0.54) | NR4A2CYP2C9NPC1RAB9AGRM5 | |
| SCHEMBL3663129 | 0.83 | HRH4 (0.49) | NR4A2CYP2C9NPC1RAB9AKMT2A | |
| SCHEMBL3367654 | 0.81 | RAB9A (0.70) | NR4A2CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3721691 | 0.81 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317673-A1 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-20100317673-A1 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317673-A1 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | IDH2, GLS, IDH1 | NR4A2 1193/4885CYP2C9 1454/4885NPC1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.